雷替曲塞联合铂类在中晚期食管癌化疗中的疗效分析

Analysis of the Curative Effect of Raltitrexed Combined with Platinum in the Chemotherapy of Advanced Esophageal Cancer

目的分析在中晚期食管癌化疗中应用雷替曲塞联合铂类的疗效。方法随机选取2017年1月—2020年12月该院收治的60例中晚期食管癌患者为研究对象,以随机数表法分成治疗组、对照组,各30例。对照组采取TP方案(多西他赛+铂类)进行化疗,治疗组采用雷替曲塞+铂类进行化疗,均化疗2个周期后评价治疗效果、不良反应、血清肿瘤标志物、免疫功能。结果治疗组治疗总有效率为83.33%,显著较对照组的60.00%高,差异有统计学意义(χ^(2)=4.021,P<0.05);治疗组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平均明显较对照组高,差异有统计学意义(t=2.276、2.029、2.342,P<0.05);治疗组CEA、SCC、CA199、CA125水平显著较对照组低,差异有统计学意义(t=2.993、2.585、2.083、2.227,P<0.05);治疗组不良反应发生率仅为13.33%,对照组为36.67%,治疗组明显较对照组低,差异有统计学意义(χ^(2)=4.355,P<0.05)。结论在中晚期食管癌化疗中,雷替曲塞+铂类化疗效果明显优于TP方案,可促进疗效升高,降低不良反应,同时还可改善机体免疫功能,降低血清肿瘤标志物,应用效果理想。

Objective To analyze the efficacy of raltitrexed combined with platinum in the chemotherapy of advanced esophageal cancer.Methods Randomly selected 60 patients with advanced esophageal cancer treated in the hospital from January 2017 to December 2020 were randomly divided into treatment group and control group,with 30 cases in each group.The control group took the TP regimen(docetaxel+platinum)for chemotherapy.The treatment group was treated with raltitrexed+platinum for chemotherapy.After 2 cycles of chemotherapy,the treatment effect,adverse reactions,serum tumor markers,and immune function were evaluated.Results The total effective rate of treatment in the treatment group was 83.33%,which was significantly higher than the 60.00%in the control group,and the difference was statistically significant(χ^(2)=4.021,P<0.05).The levels of CD4^(+),CD8^(+) and CD4^(+)/CD8^(+) in the treatment group were significantly higher than those in the control group,and the difference was statistically significant(t=2.276,2.029,2.342,P<0.05).The levels of CEA,SCC,CA199 and CA125 in the treatment group were significantly lower than those in the control group,and the difference was statistically significant(t=2.993,2.585,2.083,2.227,P<0.05).The incidence of adverse reactions was only 13.33%in the treatment group and 36.67%in the control group.The treatment group was significantly lower than the control group,and the difference was statistically significant(χ^(2)=4.355,P<0.05).Conclusion In the chemotherapy of advanced esophageal cancer,the effect of raltitrexed+platinum chemotherapy is significantly better than that of the TP regimen,which can promote the increase of the curative effect and reduce the adverse reactions.At the same time,it can also improve the body's immune function,reduce serum tumor markers,and the application effect is ideal.